AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21406472 — intervention group
Group type: COMPARATOR
Intervention: Single-agent lapatinib (L)
Number of subjects: 0
Study 19106583 — intervention group
Group type: EXPERIMENTAL
Intervention: S‐1 plus Lentinan (LNT)
Number of subjects: 150
Study 19106583 — intervention group
Group type: COMPARATOR
Intervention: S‐1 alone
Number of subjects: 150
Study 16431307 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive medical treatment (biofeedback training and/or laxative treatment)
Number of subjects: 119
Study 12717482 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 394
Study 12717482 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 394
Study 10848778 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum levels of ICTP
Number of subjects: 313
Study 10848778 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum levels of BAP
Number of subjects: 313
Study 10848778 — intervention group
Group type: EXPERIMENTAL
Intervention: ICTP
Number of subjects: 313
Study 8646485 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy and HSCT (specific regimens not detailed)
Number of subjects: 42
Study 1334515 — intervention group
Group type: EXPERIMENTAL
Intervention: Zileuton (5-lipoxygenase inhibitor)
Number of subjects: 0
Study 1334515 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6367812 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybuprocaine 0.4% eye drops, one drop instilled 10 and 5 minutes preoperatively
Number of subjects: 68
Study 6367812 — intervention group
Group type: COMPARATOR
Intervention: Placebo eye drops, one drop instilled 10 and 5 minutes preoperatively
Number of subjects: 68
Study 30732707 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVR
Number of subjects: 274
Study 30732707 — intervention group
Group type: COMPARATOR
Intervention: SAVR
Number of subjects: 274
Study 28915871 — intervention group
Group type: EXPERIMENTAL
Intervention: Key feature arm (n = 30)
Number of subjects: 56
Study 28915871 — intervention group
Group type: COMPARATOR
Intervention: Systematic arm (n = 26)
Number of subjects: 56
Study 26530749 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine-based chemoradiation
Number of subjects: 74
Study 26530749 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine-based chemoradiation
Number of subjects: 74
Study 24075485 — intervention group
Group type: EXPERIMENTAL
Intervention: Sivelestat (0.2 mg/kg per hour)
Number of subjects: 13
Study 24075485 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 13
Study 21785082 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast displacement
Number of subjects: 54
Study 21785082 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast displacement plus lead shielding
Number of subjects: 54
Study 21785082 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 54
Study 19196290 — intervention group
Group type: EXPERIMENTAL
Intervention: Outreach placement (5-week block)
Number of subjects: 49
Study 19196290 — intervention group
Group type: COMPARATOR
Intervention: Hospital-based training
Number of subjects: 49
Study 17223855 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin 250 mg twice daily for 2 days
Number of subjects: 12
Study 17223855 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit juice 200 ml three times daily for 2 days
Number of subjects: 12
Study 17223855 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 15452189 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-existential group therapy (CEGT) with 20 sessions of weekly group therapy plus three relaxation classes (n = 154)
Number of subjects: 303
Study 15452189 — intervention group
Group type: COMPARATOR
Intervention: Control condition of three relaxation classes alone (n = 149)
Number of subjects: 303
Study 12106752 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B(6) 50 mg plus placebo pill/day
Number of subjects: 55
Study 12106752 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C 500 mg plus placebo pill/day
Number of subjects: 55
Study 12106752 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B(6) 50 mg plus vitamin C 500 mg/day
Number of subjects: 55
Study 12106752 — intervention group
Group type: COMPARATOR
Intervention: 2 placebo pills/day (control)
Number of subjects: 55
Study 12106752 — intervention group
Group type: EXPERIMENTAL
Intervention: All participants (collapsed data)
Number of subjects: 55
Study 10477777 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg of enoxaparin
Number of subjects: 1102
Study 10477777 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1102
Study 10477777 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of enoxaparin
Number of subjects: 1102
Study 8529731 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant systemic cisplatin, methotrexate and vinblastine chemotherapy
Number of subjects: 69
Study 2311149 — intervention group
Group type: EXPERIMENTAL
Intervention: Edrophonium 1 mg.kg‐1 (single dose)
Number of subjects: 20
Study 2311149 — intervention group
Group type: EXPERIMENTAL
Intervention: Edrophonium 0.2 mg.kg‐1 followed by 0.8 mg.kg‐1 (divided doses)
Number of subjects: 20
Study 367874 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon (administered intramuscularly and intravenously)
Number of subjects: 9
Study 367874 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 367874 — intervention group
Group type: COMPARATOR
Intervention: Anticholinergic drugs
Number of subjects: 9
Study 6832198 — intervention group
Group type: EXPERIMENTAL
Intervention: Alinidine (0.5 mg/kg i.v.)
Number of subjects: 2
Study 6832198 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (0.1 mg/kg i.v.)
Number of subjects: 2
Study 31766467 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive support ventilation (ASV)
Number of subjects: 15
Study 31766467 — intervention group
Group type: COMPARATOR
Intervention: Pressure-control ventilation (PCV)
Number of subjects: 15
Study 31766467 — intervention group
Group type: COMPARATOR
Intervention: Volume-control ventilation (VCV)
Number of subjects: 15
Study 29750027 — intervention group
Group type: EXPERIMENTAL
Intervention: tiotropium/olodaterol
Number of subjects: 184
Study 29750027 — intervention group
Group type: COMPARATOR
Intervention: tiotropium
Number of subjects: 184
Study 26324738 — intervention group
Group type: EXPERIMENTAL
Intervention: Cixutumumab 10 mg/kg and the same antiestrogen (arm A)
Number of subjects: 93
Study 26324738 — intervention group
Group type: EXPERIMENTAL
Intervention: Cixutumumab alone (arm B)
Number of subjects: 93
Study 26324738 — intervention group
Group type: EXPERIMENTAL
Intervention: Cixutumumab (10 mg/kg) with or without antiestrogen
Number of subjects: 93
Study 26324738 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower IR-A, IR-B, and total IR mRNA expression in tumor tissue (regardless of treatment)
Number of subjects: 93
Study 23963691 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasojejunal tube (NJT)
Number of subjects: 68
Study 23963691 — intervention group
Group type: COMPARATOR
Intervention: Jejunostomy tube (JT)
Number of subjects: 68
Study 22960612 — intervention group
Group type: EXPERIMENTAL
Intervention: d‐cycloserine 50mg
Number of subjects: 27
Study 22960612 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0mg d‐cycloserine)
Number of subjects: 27
Study 19912599 — intervention group
Group type: EXPERIMENTAL
Intervention: 12+12 weeks of varenicline
Number of subjects: 0
Study 19912599 — intervention group
Group type: COMPARATOR
Intervention: 12 weeks of varenicline
Number of subjects: 0
Study 19912599 — intervention group
Group type: COMPARATOR
Intervention: 12 weeks of bupropion
Number of subjects: 0
Study 19912599 — intervention group
Group type: COMPARATOR
Intervention: 12 weeks of placebo
Number of subjects: 0
Study 18829901 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioresorbable calcium phosphate cement
Number of subjects: 120
Study 18829901 — intervention group
Group type: COMPARATOR
Intervention: Autogenous iliac bone graft
Number of subjects: 120
Study 15636257 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary Sjögren syndrome (PS)
Number of subjects: 60
Study 15636257 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary Sjögren syndrome (SS)
Number of subjects: 60
Study 15636257 — intervention group
Group type: COMPARATOR
Intervention: Healthy individuals
Number of subjects: 60
Study 11244227 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriol cream (Daivonex/Dovonex) used daily combined with UVB treatments twice weekly
Number of subjects: 0
Study 11244227 — intervention group
Group type: COMPARATOR
Intervention: Emollient used daily combined with UVB treatments three times weekly
Number of subjects: 0
Study 9420370 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of a companion animal (dog)
Number of subjects: 23
Study 9420370 — intervention group
Group type: COMPARATOR
Intervention: No companion animal (control)
Number of subjects: 23
Study 8123271 — intervention group
Group type: EXPERIMENTAL
Intervention: Heated breathing tubes at 30 degrees C (Group 2)
Number of subjects: 26
Study 8123271 — intervention group
Group type: EXPERIMENTAL
Intervention: Heated breathing tubes at 36 degrees C (Group 3)
Number of subjects: 26
Study 8123271 — intervention group
Group type: COMPARATOR
Intervention: Unheated breathing tubes (Group 1)
Number of subjects: 26
Study 3333530 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary fat intake modification (reduced from 39% to 24% of energy, increased P/S ratio from 0.2 to 0.4-1.2)
Number of subjects: 0
Study 3333530 — intervention group
Group type: COMPARATOR
Intervention: Control group (baseline period)
Number of subjects: 0
Study 29346916 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplicial configuration model
Number of subjects: 0
Study 29346916 — intervention group
Group type: COMPARATOR
Intervention: Randomized counterparts
Number of subjects: 0
Study 26578718 — intervention group
Group type: EXPERIMENTAL
Intervention: Patellar tendon (PT) graft
Number of subjects: 65
Study 26578718 — intervention group
Group type: COMPARATOR
Intervention: Hamstring tendon (HS) graft
Number of subjects: 65
Study 26578718 — intervention group
Group type: EXPERIMENTAL
Intervention: Both PT and HS grafts
Number of subjects: 65
Study 22014603 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable dosing of intravitreal bevacizumab (1.25 mg/0.05 mL)
Number of subjects: 120
Study 22014603 — intervention group
Group type: COMPARATOR
Intervention: Fixed-interval dosing of intravitreal bevacizumab (every 4 to 6 weeks)
Number of subjects: 120
Study 20577706 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical lidocaine patches (LP) as an add-on to established pain medication
Number of subjects: 87
Study 20577706 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical lidocaine patches (LP)
Number of subjects: 87
Study 17498072 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential therapy with rFVIIa and APCC
Number of subjects: 4
Study 15718407 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD diaphragms
Number of subjects: 20
Study 15718407 — intervention group
Group type: COMPARATOR
Intervention: Control diaphragms
Number of subjects: 20
Study 11756906 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal saline solution injection (1‐2 mL boluses; mean volume 30 mL)
Number of subjects: 100
Study 11756906 — intervention group
Group type: COMPARATOR
Intervention: Bipolar electrocoagulation (20 W, 10‐sec applications; mean time 100 sec)
Number of subjects: 100
Study 11756906 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal saline solution injection
Number of subjects: 100
Study 11756906 — intervention group
Group type: COMPARATOR
Intervention: Bipolar electrocoagulation
Number of subjects: 100
Study 10923432 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IP)
Number of subjects: 30
Study 10923432 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 7979927 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training (progressive interval training with bicycle exercises, heel lifts, and step-climbing, performed twice weekly for 45 minutes over 3 months)
Number of subjects: 24
Study 7979927 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training
Number of subjects: 24
Study 7979927 — intervention group
Group type: COMPARATOR
Intervention: Control group (untrained)
Number of subjects: 24
Study 3381069 — intervention group
Group type: COMPARATOR
Intervention: Conventional proctectomy and Brooke ileostomy
Number of subjects: 54
Study 3381069 — intervention group
Group type: EXPERIMENTAL
Intervention: Mucosal proctectomy with ileoanal anastomosis (IAA)
Number of subjects: 54
Study 30673864 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine (1.25% NAC)
Number of subjects: 60
Study 30673864 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine (0.2% CHX)
Number of subjects: 60
Study 30673864 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 28927673 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (40 to 60 mg/day for 14 days)
Number of subjects: 97
Study 28927673 — intervention group
Group type: COMPARATOR
Intervention: ACTH (40 to 60 IU every other day for 14 days)
Number of subjects: 97
Study 28927673 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 97
Study 25909526 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine-based mouthrinse (Peridex)
Number of subjects: 23
Study 25909526 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzymatic-based mouthrinse (Biotène)
Number of subjects: 23
Study 25909526 — intervention group
Group type: COMPARATOR
Intervention: Sterile water (negative control)
Number of subjects: 23
Study 24898301 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 94
Study 24898301 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT)
Number of subjects: 94
Study 24898301 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 94
Study 24898301 — intervention group
Group type: EXPERIMENTAL
Intervention: MBCT and CBT
Number of subjects: 94
Study 24898301 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c levels
Number of subjects: 94
Study 22045924 — intervention group
Group type: EXPERIMENTAL
Intervention: DPP4 inhibitor, sitagliptin
Number of subjects: 12
Study 22045924 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 20191713 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental treatments
Number of subjects: 0
Study 20191713 — intervention group
Group type: COMPARATOR
Intervention: Comparison treatments
Number of subjects: 0
Study 17590070 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-generation remote emergency medical oxygen (REMO(2)) system
Number of subjects: 6
Study 15325891 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0% C31G
Number of subjects: 36
Study 15325891 — intervention group
Group type: COMPARATOR
Intervention: Extra Strength Gynol II (3% nonoxynol-9)
Number of subjects: 36
Study 11449608 — intervention group
Group type: COMPARATOR
Intervention: Cromolyn
Number of subjects: 20
Study 11449608 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 20
Study 11449608 — intervention group
Group type: EXPERIMENTAL
Intervention: Both medications
Number of subjects: 20
Study 9449907 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% podofilox gel
Number of subjects: 326
Study 9449907 — intervention group
Group type: COMPARATOR
Intervention: Vehicle gel
Number of subjects: 326
Study 7637723 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole (200 mg per day)
Number of subjects: 43
Study 7637723 — intervention group
Group type: COMPARATOR
Intervention: No ketoconazole (Control)
Number of subjects: 43
Study 2699466 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxofylline (400 mg twice daily)
Number of subjects: 139
Study 2699466 — intervention group
Group type: COMPARATOR
Intervention: Slow-release theophylline (300 mg twice daily)
Number of subjects: 139
Study 7135 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 300 mg
Number of subjects: 8
Study 7135 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 100 mg
Number of subjects: 8
Study 7135 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 200 mg
Number of subjects: 8
Study 7135 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 31236888 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 g of oral DKP daily (Group A)
Number of subjects: 117
Study 31236888 — intervention group
Group type: COMPARATOR
Intervention: 1 tablet of Diane‐35 orally daily (Group B)
Number of subjects: 117
Study 31236888 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 g of oral DKP daily plus 1 tablet of Diane‐35 orally daily (Group C)
Number of subjects: 117
Study 27900771 — intervention group
Group type: EXPERIMENTAL
Intervention: LAP block
Number of subjects: 45
Study 27900771 — intervention group
Group type: COMPARATOR
Intervention: TAP block
Number of subjects: 45
Study 26390350 — intervention group
Group type: EXPERIMENTAL
Intervention: Delefilcon A
Number of subjects: 39
Study 23378417 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol (25,000 IU) therapy every 2 weeks
Number of subjects: 43
Study 23378417 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 20188537 — intervention group
Group type: EXPERIMENTAL
Intervention: Helical TomoTherapy (HT)
Number of subjects: 10
Study 20188537 — intervention group
Group type: COMPARATOR
Intervention: Dynamic Conformal Arc Therapy (DCAT)
Number of subjects: 10
Study 20014523 — intervention group
Group type: EXPERIMENTAL
Intervention: Physically attractive woman
Number of subjects: 2
Study 20014523 — intervention group
Group type: COMPARATOR
Intervention: Unattractive woman
Number of subjects: 2
Study 20014523 — intervention group
Group type: EXPERIMENTAL
Intervention: Physically attractive condition
Number of subjects: 2
Study 20014523 — intervention group
Group type: COMPARATOR
Intervention: Unattractive condition
Number of subjects: 2
Study 17595892 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg i.v. (administered over 30 min)
Number of subjects: 90
Study 17595892 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 40 mg i.v. (administered over 30 min)
Number of subjects: 90
Study 17595892 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 80 mg i.v. + 8 mg/h (for 23.5 h)
Number of subjects: 90
Study 17595892 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 80 mg i.v. + 8 mg/h (for 23.5 h)
Number of subjects: 90
Study 15077462 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment with loperamide 2‐6 mg/day for 2 months
Number of subjects: 22
Study 15077462 — intervention group
Group type: EXPERIMENTAL
Intervention: Yogic intervention consisting of 12 asanas and Surya Nadi pranayama two times a day for 2 months
Number of subjects: 22
Study 11172835 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant FSH (rFSH)
Number of subjects: 578
Study 11172835 — intervention group
Group type: COMPARATOR
Intervention: human menopausal gonadotropins (hMG)
Number of subjects: 578
Study 9707184 — intervention group
Group type: COMPARATOR
Intervention: Antihypertensive therapy before randomization (tPA 9%, placebo 9%)
Number of subjects: 624
Study 9707184 — intervention group
Group type: COMPARATOR
Intervention: Antihypertensive therapy after randomization (tPA 24%, placebo 29%)
Number of subjects: 624
Study 9707184 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive therapy after randomization for tPA patients
Number of subjects: 624
Study 1515758 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 20
Study 1515758 — intervention group
Group type: COMPARATOR
Intervention: Reserpine + Frusemide
Number of subjects: 20
Study 6088252 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (200 mg)
Number of subjects: 7
Study 6088252 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (400 mg)
Number of subjects: 7
Study 6088252 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg)
Number of subjects: 7
Study 6088252 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (300 mg)
Number of subjects: 7
Study 6088252 — intervention group
Group type: COMPARATOR
Intervention: Triprolidine (10 mg)
Number of subjects: 7
Study 31533125 — intervention group
Group type: COMPARATOR
Intervention: Under-normal weight group (<25 kg/m2)
Number of subjects: 500
Study 31533125 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight group (25-29.99 kg/m2)
Number of subjects: 500
Study 31533125 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese group (≥30 kg/m2)
Number of subjects: 500
Study 29996734 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic ultrasound and self-performed stretching of the plantar fascia and calf muscles
Number of subjects: 54
Study 29996734 — intervention group
Group type: COMPARATOR
Intervention: Sham ultrasound and self-performed stretching of the plantar fascia and calf muscles
Number of subjects: 54
Study 27619190 — intervention group
Group type: EXPERIMENTAL
Intervention: Benznidazole (5mg/kg/day for 60 days)
Number of subjects: 14
Study 27619190 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 14
Study 23622351 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face (FTF) weight management clinic
Number of subjects: 20
Study 23622351 — intervention group
Group type: COMPARATOR
Intervention: Virtual reality (VR) clinic
Number of subjects: 20
Study 21159021 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 μg·kg(‐1) of clonidine
Number of subjects: 120
Study 21159021 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 μg·kg(‐1) of clonidine
Number of subjects: 120
Study 21159021 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 μg·kg(‐1) of clonidine
Number of subjects: 120
Study 19525114 — intervention group
Group type: EXPERIMENTAL
Intervention: Tandem stance (TS)
Number of subjects: 10
Study 19525114 — intervention group
Group type: EXPERIMENTAL
Intervention: Tandem stance blind folded (TSBF)
Number of subjects: 10
Study 19525114 — intervention group
Group type: EXPERIMENTAL
Intervention: Tandem stance on a balance board (TSBB)
Number of subjects: 10
Study 19525114 — intervention group
Group type: COMPARATOR
Intervention: Parallel stance (PS)
Number of subjects: 10
Study 17178490 — intervention group
Group type: EXPERIMENTAL
Intervention: Open surgery (high condylectomy and disc repositioning)
Number of subjects: 20